ReviewExpert review of molecular diagnostics2014
Glioma diagnostics and biomarkers: an ongoing challenge in the field of medicine and science.
Review in Expert review of molecular diagnostics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed.
- Bioinformatics analysis of DLGAP5 as a biomarker in lung adenocarcinoma: implications for immune infiltration and targeted therapy.Discover oncology · 2025Article
- TMEM35B as a novel biomarker for diagnosing gliomas.Biomarkers in medicine · 2024Article
- Blocking TGF-β- and Epithelial-to-Mesenchymal Transition (EMT)-mediated activation of vessel-associated mural cells in glioblastoma impacts tumor angiogenesis.Free neuropathology · 2024Article
- Novel exosome-related risk signature as prognostic biomarkers in glioblastoma.Frontiers in immunology · 2023Article
- Multifaceted roles of extracellular RNAs in different diseases.Military Medical Research · 2022Review
- Targeting miR-9 in Glioma Stem Cell-Derived Extracellular Vesicles: A Novel Diagnostic and Therapeutic Biomarker.Translational oncology · 2022Article
- Sonobiopsy for minimally invasive, spatiotemporally-controlled, and sensitive detection of glioblastoma-derived circulating tumor DNA.Theranostics · 2022Article
- A Potential Prognostic Biomarker for Glioma: Aldo-Keto Reductase Family 1 Member B1.Computational intelligence and neuroscience · 2022Article
- Myelin-associated proteins are potential diagnostic markers in patients with primary brain tumour.Annals of medicine · 2021Article
- Screening and identification of LMNB1 and DLGAP5, two key biomarkers in gliomas.Bioscience reports · 2021Article
- Temporal Muscle Thickness is an Independent Prognostic Biomarker in Patients with Glioma: Analysis of 261 Cases.Cancer management and research · 2021Article
- A review of gliomas-related proteins. Characteristics of potential biomarkers.American journal of cancer research · 2021Review
- Peripheral Inflammatory Blood Markers in Diagnosis of Glioma and IDH Status.Journal of neurosciences in rural practice · 2021Article
- Nanodelivery Systems Targeting Epidermal Growth Factor Receptors for Glioma Management.Pharmaceutics · 2020Review
- Current Perspectives on Clinical Use of Exosomes as a Personalized Contrast Media and Theranostics.Cancers · 2020Review
- Article
- Establishment of age group classification for risk stratification in glioma patients.BMC neurology · 2020Article
- Proteome of Glioblastoma-Derived Exosomes as a Source of Biomarkers.Biomedicines · 2020Article
- lncRNA SNHG16 Exerts Oncogenic Functions in Promoting Proliferation of Glioma Through Suppressing p21.Pathology oncology research : POR · 2020Article
- Cerebrospinal fluid biomarkers for brain tumor detection: clinical roles and current progress.American journal of translational research · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Glioma is the most common brain tumor. For the more aggressive form, glioblastoma, standard treatment includes surgical resection, irradiation with adjuvant temozolomide and, on recurrence, experimental chemotherapy. However, the survival of patients remains poor. There is a critical need for minimally invasive biomarkers for diagnosis and as measures of response to therapeutic interventions. Glioma shed extracellular vesicles (EVs), which invade the surrounding tissue and circulate within both the cerebrospinal fluid and the systemic circulation. These tumor-derived EVs and their content serve as an attractive source of biomarkers. In this review, we discuss the current state of the art of biomarkers for glioma with emphasis on their EV derivation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.